

Oliver M Grauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9230449/publications.pdf>

Version: 2024-02-01

77
papers

6,387
citations

147801

31
h-index

91884

69
g-index

81
all docs

81
docs citations

81
times ranked

11322
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. <i>Brain Pathology</i> , 2009, 19, 674-693.	4.1	2,884
2	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 678-688.	13.7	384
3	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. <i>Neuro-Oncology</i> , 2009, 11, 394-402.	1.2	203
4	CD4 ⁺ FoxP3 ⁺ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress anti-glioma immune responses in vivo. <i>International Journal of Cancer</i> , 2007, 121, 95-105.	5.1	199
5	Toll-like receptors on regulatory T cells: expanding immune regulation. <i>Trends in Immunology</i> , 2006, 27, 387-393.	6.8	194
6	Pegylated liposomal doxorubicin efficacy in patients with recurrent high-grade glioma. <i>Cancer</i> , 2004, 100, 1199-1207.	4.1	189
7	Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. <i>Brain</i> , 2010, 133, 2852-2865.	7.6	189
8	CD4 ⁺ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 807-818.	1.2	129
9	Microglial Phagocytosis of Apoptotic Inflammatory T Cells Leads to Down-Regulation of Microglial Immune Activation. <i>Journal of Immunology</i> , 2001, 167, 5004-5010.	0.8	128
10	TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas. <i>Journal of Immunology</i> , 2008, 181, 6720-6729.	0.8	127
11	Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2019, 141, 83-94.	2.9	102
12	New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells. <i>PLoS ONE</i> , 2013, 8, e66987.	2.5	86
13	RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study. <i>BMC Cancer</i> , 2009, 9, 308.	2.6	83
14	Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. <i>International Journal of Cancer</i> , 2008, 122, 1794-1802.	5.1	78
15	Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. <i>International Journal of Cancer</i> , 2013, 132, 843-853.	5.1	77
16	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <i>Cancer Immunology Research</i> , 2019, 7, 1910-1927.	3.4	74
17	Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. <i>Journal of Neuroimmunology</i> , 2004, 148, 63-73.	2.3	64
18	Salvage therapy in patients with glioblastoma. <i>Cancer</i> , 2003, 98, 2678-2686.	4.1	63

#	ARTICLE	IF	CITATIONS
19	Targeting B cells in relapsingâ€“remitting multiple sclerosis: from pathophysiology to optimal clinical management. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 51-66.	3.5	62
20	Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 422-425.	1.7	57
21	<i>In vivo</i> Colocalization of Antigen and CpG within Dendritic Cells Is Associated with the Efficacy of Cancer Immunotherapy. <i>Cancer Research</i> , 2008, 68, 5390-5396.	0.9	55
22	Ibuprofen and Diclofenac Restrict Migration and Proliferation of Human Glioma Cells by Distinct Molecular Mechanisms. <i>PLoS ONE</i> , 2015, 10, e0140613.	2.5	54
23	Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas?. <i>Neurosurgery</i> , 2019, 84, 1214-1224.	1.1	54
24	Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. <i>Journal of Neurosurgery</i> , 2021, 134, 426-436.	1.6	53
25	Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. <i>Histochemistry and Cell Biology</i> , 2002, 117, 351-362.	1.7	48
26	Brain invasion and the risk of seizures in patients with meningioma. <i>Journal of Neurosurgery</i> , 2019, 130, 789-796.	1.6	48
27	Neurocognitive decline in HIV patients is associated with ongoing Tâ€“cell activation in the cerebrospinal fluid. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 906-919.	3.7	40
28	Human CCR5 ^{high} effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. <i>Brain</i> , 2019, 142, 3411-3427.	7.6	39
29	Ineffective treatment of PML with pembrolizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e627.	6.0	39
30	Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF- β 2. <i>Journal of Neuro-Oncology</i> , 2007, 82, 151-161.	2.9	37
31	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. <i>Neuro-Oncology</i> , 2020, 22, 1030-1043.	1.2	35
32	Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. <i>Cancer Research and Treatment</i> , 2017, 49, 548-552.	3.0	31
33	Health-related quality of life and neurocognitive functioning with lomustineâ€“temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1444-1453.	10.7	29
34	Muscle Cramps and Neuropathies in Patients with Allogeneic Hematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. <i>PLoS ONE</i> , 2012, 7, e44922.	2.5	28
35	A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 293.	1.6	27
36	The evolution of cranial meningioma surgeryâ€“a single-center 25-year experience. <i>Acta Neurochirurgica</i> , 2018, 160, 1801-1812.	1.7	27

#	ARTICLE	IF	CITATIONS
37	The genetic landscape of choroid plexus tumors in children and adults. <i>Neuro-Oncology</i> , 2021, 23, 650-660.	1.2	26
38	Selective cancer-germline gene expression in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 2008, 88, 273-280.	2.9	24
39	Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme. <i>European Radiology</i> , 2013, 23, 2868-2879.	4.5	24
40	Maintenance Therapy with 13-cis Retinoid Acid in High-Grade Glioma at Complete Response After First-Line Multimodal Therapy – A Phase-II Study. <i>Journal of Neuro-Oncology</i> , 2004, 68, 79-86.	2.9	22
41	The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). <i>Frontiers in Immunology</i> , 2021, 12, 787307.	4.8	21
42	Multimodal Molecular Imaging of the Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1225, 71-87.	1.6	20
43	ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. <i>Neuro-Oncology</i> , 2017, 19, vi13-vi14.	1.2	17
44	Recurrent cardiac arrest caused by lateral medulla oblongata infarction. <i>BMJ Case Reports</i> , 2009, 2009, bcr0220091625-bcr0220091625.	0.5	16
45	The role of ion channels in malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2015, 125, 225-235.	2.9	15
46	Glioma Tissue Obtained by Modern Ultrasonic Aspiration with a Simple Sterile Suction Trap for Primary Cell Culture and Pathological Evaluation. <i>European Surgical Research</i> , 2014, 53, 37-42.	1.3	14
47	Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2131-2141.	6.4	14
48	Brain invasion in meningiomas: does surgical sampling impact specimen characteristics and histology?. <i>Neurosurgical Review</i> , 2020, 43, 793-800.	2.4	12
49	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 117-130.	2.9	12
50	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	1.2	11
51	Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. <i>British Journal of Neurosurgery</i> , 2019, , 1-7.	0.8	11
52	MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. <i>International Journal of Cancer</i> , 2021, 148, 1695-1707.	5.1	11
53	Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). <i>Journal of Neuro-Oncology</i> , 2011, 104, 801-809.	2.9	10
54	Phase I/II trial of meclufenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy – the MecMeth/NOA-24 trial. <i>Trials</i> , 2022, 23, 57.	1.6	10

#	ARTICLE	IF	CITATIONS
55	A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. <i>Brain</i> , 2023, 146, 977-990.	7.6	10
56	Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas. <i>Scientific Reports</i> , 2022, 12, 6769.	3.3	10
57	Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5985.	4.1	8
58	Bilateral vertebral artery occlusion with retrograde basilar flow in three cases of giant cell arteritis. <i>BMJ Case Reports</i> , 2009, 2009, bcr0720080488-bcr0720080488.	0.5	8
59	RTHP-22. INFLAMMATORY RESPONSE AFTER MODIFIED NANOTHERM AND RADIOTHERAPY OF RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi178-vi179.	1.2	6
60	A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. <i>Frontiers in Neurology</i> , 2018, 9, 383.	2.4	6
61	Predicting postoperative seizure development in meningiomas – Analyses of clinical, histological and radiological risk factors. <i>Clinical Neurology and Neurosurgery</i> , 2021, 200, 106315.	1.4	6
62	Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT. <i>Journal of Neurosurgery</i> , 2021, 135, 845-854.	1.6	6
63	Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management. <i>Cancers</i> , 2022, 14, 541.	3.7	5
64	Interdisciplinary Decision Making in Hemorrhagic Stroke Based on CT Imaging – Differences Between Neurologists and Neurosurgeons Regarding Estimation of Patients' Symptoms, Glasgow Coma Scale, and National Institutes of Health Stroke Scale. <i>Frontiers in Neurology</i> , 2019, 10, 997.	2.4	4
65	Toxicity Reduction after Craniospinal Irradiation via Helical Tomotherapy in Patients with Medulloblastoma: A Unicentric Retrospective Analysis. <i>Cancers</i> , 2021, 13, 501.	3.7	4
66	An enigmatic case of cortical anopsia: Antemortem diagnosis of a 14-3-3 negative Heidenhain-variant MM1-sCJD. <i>Prion</i> , 2020, 14, 24-28.	1.8	2
67	Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?. , 2010, , 133-157.		2
68	Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143. <i>Journal of Clinical Oncology</i> , 2017, 35, 2001-2001.	1.6	2
69	Risk factors for preoperative seizures in intracranial meningiomas. <i>Journal of Neurosurgical Sciences</i> , 2020, , .	0.6	1
70	QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143. <i>Neuro-Oncology</i> , 2015, 17, v189.2-v189.	1.2	0
71	CBIO-19IBUPROFEN AND DICLOFENAC INHIBIT MIGRATION AND PROLIFERATION OF HUMAN GLIOMA CELL LINES IN VITRO. <i>Neuro-Oncology</i> , 2015, 17, v58.5-v59.	1.2	0
72	SURG-32. COMBINED INTRACAVITARY THERMOTHERAPY WITH IRON-OXIDE NANOPARTICLES AND RADIOTHERAPY AS A PROMISING TREATMENT MODALITY IN RECURRENT GBM. <i>Neuro-Oncology</i> , 2017, 19, vi241-vi242.	1.2	0

#	ARTICLE	IF	CITATIONS
73	QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi218-vi219.	1.2	0
74	ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL. <i>Neuro-Oncology</i> , 2019, 21, vi25-vi26.	1.2	0
75	SURG-12. "NANOPASTE" THERAPY AS POTENTIAL TREATMENT OPTION FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi242-vi242.	1.2	0
76	BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi11.	1.2	0
77	Classical and disease-specific quality indicators in glioma surgery"Development of a quality checklist to improve treatment quality in glioma patients. <i>Neuro-Oncology Practice</i> , 2022, 9, 59-67.	1.6	0